Tucuvi, which describes itself as an AI care management company, said it is joining the Microsoft for Startups Pegasus Program, an initiative that connects selected companies to Microsoft's enterprise customer ecosystem and go-to-market channels. The announcement was made from Boston on 15 October 2026. Tucuvi said the selection comes as it scales its platform across health systems, and that through the program it will be able to bring its clinically governed approach to AI care management to more organizations on a single platform spanning administrative and clinical workflows.
Buying through Microsoft Marketplace
Health systems and life sciences companies can contract Tucuvi directly through Microsoft Marketplace, the company said, or apply that spend against the Microsoft Azure commitment they have already made, using a procurement path their organization has already approved.
LOLA and the care platform
Tucuvi Health Manager is the company's AI care management platform. At its centre is LOLA®, described as a clinical voice AI agent that holds inbound and outbound phone conversations with patients in natural language, follows configurable clinical and administrative protocols, captures structured information and escalates cases where human intervention is needed. The platform is omnichannel and extends the same workflows to text. LOLA integrates with Microsoft Foundry, which serves as the layer for deploying and monitoring the models behind its conversational capabilities, and with Azure Speech for the voice layer. Tucuvi said more than 80 health settings run over 50 workflow types on the platform, including post-discharge follow-up and transitional care management, chronic care management check-ins, medication adherence outreach, prescription refills and scheduling.
Clinical governance and EU certification
Clinical governance is built into the platform: organizations can use evidence-based protocols or configure their own, define escalation criteria and workflow actions, and retain oversight of patient interactions and clinical decisions. Tucuvi said its technology is developed to medical-device safety standards and is certified as Class IIb Software as a Medical Device in the European Union.
